Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatologic disease of childhood with an incidence of 19.8 per 100,000 Caucasian children under the age of 16 1 . In Turkey, the prevalence of JIA is reported to be 64/100,000 children 2 . JIA represents a group of heterogeneous diseases that are classified as arthritis of unknown origin and have onset before the age of 16 years 3 .
JIA is divided into six distinct categories according to the International League of Associations for Rheumatology (ILAR) classification: oligoarticular, polyarticular, systemic, psoriatic, enthesitis related and unclassified arthritis 4, 5 .
The principle aim of JIA treatment is to achieve clinically inactive disease while preventing long-term morbidities. A variety of therapies are currently used in the management of JIA, including both biologic and non-biologic diseasemodifying anti-rheumatic drugs (DMARDs). In 2011, the American College of Rheumatology (ACR) published recommendations for the safest and most effective treatment of JIA 6 . Afterwards in 2014, the Childhood Arthritis and Rheumatology Research Alliance (CARRA) developed three consensus treatment plans (CTPs) for new-onset polyarticular JIA 7 .
Methotrexate (MTX) has been used for more than 25 years and is the most commonly used first-line DMARD in JIA 8 . It is a safe and inexpensive drug. However, MTX is ineffective in approximately 30% of JIA patients 8 . With the increasing availability of biologic therapies, it is important to predict and identify patients who will not benefit from MTX in order to allow these patients to start using biologic drugs in the early phases of the disease before morbidities develop. Previous studies have reported various factors that are predictive for MTX efficacy [8] [9] [10] . However, these factors may differ between ethnic groups. In this study, our aim was to define predictor factors for the response to MTX in Turkish children with oligo-and polyarticular JIA.
Material and Methods
We retrospectively reviewed the medical files of children (aged 0-18 years) seen at our hospital between May 2008 and May 2013 who were diagnosed with oligo-or polyarticular JIA and who received MTX treatment (12.5 mg/m 2 / week) for at least six months. These patients were classified as having JIA according to the ILAR criteria 4 sequencing and 12 mutations (E148Q, P369S,  F479I, M680I (G-C), M680I (G-A), I692del,  M694V, M694I, K695R, V726A, A744S, R761H) were tested in the MEFV gene. Juvenile arthritis disease activity score 71 (JADAS71) was used to evaluate disease activity. The JADAS 71 is a measure of disease activity in JIA patients and is based on four factors: (1) physician's global assessment of disease activity on a 0-10 visual analog scale (VAS); (2) parent/patient global assessment of well-being on a 0-10 VAS; (3) count of joints with active arthritis, and (4) erythrocyte sedimentation rate (ESR). It is calculated using the formula: physician's VAS + patient's VAS + count of joints with active arthritis + (ESR-20)/10. [11] [12] [13] . MTX responders were defined as patients whose disease was inactive or who had low disease activity according to JADAS71 at 6 months after MTX initiation. Patients with oligoarticular JIA were classified as having inactive disease if JADAS71 was < 1 and having low disease activity if JADAS71 was 1-2. In addition, patients with polyarticular JIA were classified as having inactive disease if JADAS71 was < 1, and having low disease activity if JADAS71 was between 1.1-3.8 14 .
The study was reviewed and approved by the ethical review committee of our hospital.
Statistical Analysis
Statistical analyses were performed using the SPSS software version 15. Descriptive analyses are presented using proportions, medians, range values as appropriate. The χ 2 /Fischer and Mann Whitney U tests were used to compare non-normally distributed variables between independent two groups. The Wilcoxon test was used to compare the non-normally distributed variables between dependent groups. The effects of different parameters (age at diagnosis, subtype of JIA [polyarticular or oligoarticular], ANA positivity, RF positivity age, active joint number, WBC count, ESR, CRP, patient/parent VAS, physician VAS, and JADAS71 at MTX initiation) on MTX response were calculated using simple logistic regression analysis. The variables for which the unadjusted P value was < 0.20 in simple logistic regression analysis were included in the full model. We reduced the model by using backward elimination of multiple logistic regression analyses and we eliminated potential risk markers using likelihood ratio tests. A P-value < 0.05 was considered a statistically significant result.
Results
A total of 116 patients were included in this study. Females (n = 76; 65.5%) outnumbered males. The median age at JIA diagnosis was 70 months (range: 7-180) while age at MTX initiation was 78 months (range: 12-183). The median duration between diagnosis and initiation of MTX treatment was 0 months (range: 0-156). The median duration of MTX treatment was 12 months (range: 6-78) months. The median follow-up after MTX initiation was 36 months (range: 12-148). Of 116 patients, 51 (43.9%) had persistent oligoarticular JIA, eight had extended oligoarticular JIA, and 57 (49.1%) had polyarticular JIA. In oligoarticular JIA patients, both disease diagnosis and MTX initiation occurred at a younger median age when compared to the polyarticular JIA patients (54 vs. 86, P = 0.007 and 66 vs. 102, P = 0.032, respectively). The median number of active joints was 4 (range: 1-36) at diagnosis and 5 (range: 1-22) at MTX initiation. There was a decrease in the range of motion in 3 (range: 0-24) and 3 (range: 0-20) joints at diagnosis and MTX initiation, respectively. At diagnosis, 58 (50%) had arthritis in the joints of the upper extremities and 57 (49.1%) had small joint arthritis. At MTX initiation, 63 (54.3%) had arthritis in the joints of the upper extremities and 59 (50.8%) had small joint arthritis. The median WBC count was 9.8 (range: 4-33.6) x10 3 /mm 3 , ESR was 49.5 (range: 12-145) mm/h, CRP was 2.86 (range: 0-14.3), patient/parent VAS was 3 (range: 2-7), physician VAS was 3 (range: 1-6), and JADAS71 was 13.15 (range: 0.5-41) at the time of MTX initiation. ANA positivity was present in 31 (26.7%) patients. Seventy-one (61.2%) patients received NSAIDs and 33 (28.4%) received systemic steroid treatment. Intra-articular steroid injection was performed in 33 (28.4%) patients.
The characteristics of MTX responders and nonresponders in the whole group and oligo-and polyarticular JIA subgroups are summarized in Table I and Table II . No significant difference was present between the MTX responders and non-responders or oligo-and polyarticular JIA subgroups in terms of age, gender, or age at MTX initiation. In the study cohort, the involvement of the small joints or upper extremity joints at disease diagnosis and MTX initiation was more frequent, ANA positivity was less frequent in MTX non-responders in comparison with MTX responders. The frequency of the polyarticular subtype, acute phase reactants (ESR, CRP) and JADAS71 at MTX initiation was higher in the MTX nonresponder group as well. (Table III) . There was no statistically significant difference between the characteristics of MTX responders and non-responders in the subgroup (oligo-and polyarticular JIA) analysis. In addition, there was no significant difference between persistent and extended oligoarticular JIA patients with regard to MTX response. At multiple logistic regression, JIA subtype and ANA positivity were independent predictors of MTX response. Oligoarticular JIA subtype was associated with a 7-fold increase (P < 0.001) and ANA positivity was associated with a 2.5-fold increase (P = 0.049) in the likelihood of MTX response Thirty-six patients had been tested for MEFV variants. Nine patients had accompanying familial Mediterranean fever (FMF) with typical fever attacks and were using colchicine (6 M694V/M694V, 1 V726A/V726A, 1 M680I/ V726A, and 1 with V726A/P369S). Fourteen were negative for the MEFV variants evaluated and 13 were heterozygous for different variants (4 for E148Q, 4 for M694V, 2 for M680I, and 1 each for A744S, V726A, and K695R). There were no fever attacks in these 27 patients. There were no differences with regard to the MEFV variants between MTX responders and non-responders. There were 22 patients positive for MEFV variants. Fourteen (63.6%) of them had oligoarticular JIA and 8 (36.4%) had polyarticular JIA. There were no significant differences with regard to JIA disease characteristics and response between patients positive for MEFV variants (n = 22) and patients negative for MEFV variants (n=14). Seven out of 9 FMF patients had oligoarticular JIA and two had polyarticular JIA. Four FMF+JIA patients were MTX non-responders. When we compared FMF+JIA patients (n = 9) with other JIA patients (n = 107), we saw that the active joint number at MTX initiation was lower in the FMF group than in the other groups (median values 2 vs 5, respectively; P = 0.031). The ratio of polyarticular JIA patients was higher in the non-FMF group than in the FMF patients (51.4% vs 22.2%, respectively); however, this difference was not statistically significant. In addition, there was no significant difference with regard to the MTX response between the two groups (non-responders 44.4% in FMF and 37.4% in non-FMF group). Of note, all FMF patients were receiving colchicine therapy at the time of JIA diagnosis.
Discussion
Among our study population primary factors associated with MTX response were involvement of small joints or upper extremity joints, polyarticular or oligoarticular subtype, acute phase reactant levels, JADAS71 values, and ANA positivity. In multiple logistic regression analysis, only the JIA subtype (oligo or polyarticular) and ANA positivity were found to be independent predictors of MTX response. Patients with oligoarticular JIA or positive ANA test have a greater probability of response to MTX treatment.
Juvenile idiopathic arthritis (JIA) is the most common cause of chronic arthritis in childhood. The principle aim of treatment for JIA is rapid disease control and the prevention of irreversible joint damage. 6 . We have included the involvement of small joints and upper extremity joints in our database and found that the patients in the MTX non-responder group tended to have more small joint/upper extremity joint involvement at disease diagnosis and at MTX initiation.
CARRA CTPs for new-onset polyarticular JIA were as follows: step-up CTP, early combination (biologic+nonbiologic DMARD) CTP, and biologic only CTP 7 . According to CARRA step-up CTP, treatment starts with a non-biologic DMARD (±prednisolone, intraarticular steroid injections), and the physician should consider increasing/changing DMARD or beginning biologic treatment if the patient does not improve substantially (physician global assessment > 2 and/or still on prednisolone) at 3 rd month visit. We may bypass the stepup CTP in patients with predictors for poor response to MTX.
An increased incidence of MEFV mutations has been shown among patients with vasculitis, chronic arthritis, and inflammatory bowel disease 17 . Ozen et al. 18 found that 6 out of 59 JIA patients, were homozygous or compound heterozygous for MEFV mutations. Özçakar et al. 17 showed that there was FMF in 3.5% of JIA patients. In our study 7.75% of patients had FMF and were treated with colchicine. Colchicine is the standard treatment of choice in FMF, but it is also used in other rheumatic disease such as vasculitis, autoinflammatory disease, and gout. Our FMF+JIA patients had a lower number of active joints at MTX initiation and all of them were receiving colchicine therapy. Colchicine may have a positive effect for arthritis control.
The limitations of our study are the retrospective design and the small number of patients.
In conclusion, we have demonstrated that oligoarticular subtype of JIA and ANA positivity are strong candidate predictors for MTX efficacy. Future prospective studies with more patients will be crucial for defining the exact factors identifying patients who are at risk of not responding to MTX treatment. These factors will help us improve our selection of the most appropriate treatment in JIA.
